|
Report No. : |
317581 |
|
Report Date : |
22.04.2015 |
IDENTIFICATION DETAILS
|
Name : |
SANIL PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
16, World Cup buk-ro 15-gil, Mapo-gu, Seoul, Korea 121-844 |
|
|
|
|
Country : |
South
Korea |
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
29.06.1998 |
|
|
|
|
Com. Reg. No.: |
105-81-93934 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Wholesale of Pharmaceuticals, Cosmetics, Chemicals. |
|
|
|
|
No. of Employees : |
10 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
South
Korea |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated incredible
economic growth and global integration to become a high-tech industrialized
economy. In the 1960s, GDP per capita was comparable with levels in the poorer
countries of Africa and Asia. In 2004, South Korea joined the trillion-dollar
club of world economies, and is currently the world's 12th largest economy. A
system of close government and business ties, including directed credit and
import restrictions, initially made this success possible. The government
promoted the import of raw materials and technology at the expense of consumer
goods, and encouraged savings and investment over consumption. The Asian
financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's
development model, including high debt/equity ratios and massive short-term
foreign borrowing. GDP plunged by 7% in 1998, and then recovered by 9% in
1999-2000. South Korea adopted numerous economic reforms following the crisis,
including greater openness to foreign investment and imports. Growth moderated
to about 4% annually between 2003 and 2007. South Korea's export focused
economy was hit hard by the 2008 global economic downturn, but quickly
rebounded in subsequent years, reaching over 6% growth in 2010. The US-Korea
Free Trade Agreement was ratified by both governments in 2011 and went into
effect in March 2012. Between 2012 and 2014, the economy experienced sluggish
growth because of external market slowdowns. The administration in 2015 is
likely to face the challenge of balancing heavy reliance on exports with developing
domestic-oriented sectors, such as services. The South Korean economy's
long-term challenges include a rapidly aging population, inflexible labor
market, dominance of large conglomerates (chaebols), and the heavy reliance on
exports, which comprise about half of GDP.
|
Source
: CIA |
|
Company Name |
SANIL
PHARMACEUTICAL CO., LTD. |
|
Registered Address |
16, World Cup buk-ro 15-gil, Mapo-gu,
Seoul, Korea |
|
Building |
|
|
Zip Code |
121-844 |
|
Tel |
+82-2-323-1236 |
|
Fax |
+82-2-323-1253 |
|
E-mail |
ssanilpharm@yahoo.co.kr |
|
Website |
|
|
Trading Address |
16, World Cup buk-ro 15-gil, Mapo-gu,
Seoul, Korea (Old Address System : 103-21, Seongsan
1-dong, Mapo-gu, Seoul, Korea) |
|
Tel |
+82-2-323-1236 |
|
Fax |
+82-2-323-1253 |
|
Other Address |
340-3, Hyeoncheon-dong, Deogyang-gu,
Goyang-si, Gyeonggi-do, Korea |
|
Tel |
|
|
Fax |
|
|
Type |
Import |
|
Industry |
Wholesale of Pharmaceuticals |
|
Main Business |
Pharmaceuticals, Cosmetics, Chemicals |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
06/29/1998 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Pharmaceuticals |
|
Sell |
Cosmetics |
|
Sell |
Chemicals |
|
Name |
Kim Jung-Hyun |
|
Address |
Suite 404-802, 79, Norumok-ro,
Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea |
|
Date of Birth |
07/18/1956 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
210,000,000 |
||||||||||||||||||
|
Employees |
10 |
||||||||||||||||||
|
Formation |
Co., Ltd by Shares |
||||||||||||||||||
|
Bank Details |
Kookmin Bank-Sungsan Dong Branch |
||||||||||||||||||
|
Corporate Registered No. |
110111-1560550 |
||||||||||||||||||
|
Business Registered No. |
105-81-93934 |
||||||||||||||||||
|
Permit & Licenses |
N/A |
||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||
|
Company History |
1996 Established as SANIL PHARMACEUTICAL CO.(Sole Proprietorship) 06/29/1998 Incorporated as the present name |
||||||||||||||||||
|
|
|
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Kim Jung-Hyun |
Male |
Korean |
06/29/1998 |
|
Director |
Mr. |
Kim Kyung-Hyun |
Male |
Korean |
06/29/1998 |
|
Director |
M/S. |
La Kyung-Ok |
Female |
Korean |
06/29/1998 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
2014 |
|
|
|
|
2013 |
12,803,737,000 |
9,887,197,000 |
190,451,000 |
|
2012 |
14,918,541,000 |
9,780,604,000 |
186,919,000 |
|
2011 |
13,958,606,000 |
9,350,890,000 |
478,465,000 |
|
2010 |
14,928,000,000 |
8,477,000,000 |
793,000,000 |
|
2009 |
14,307,000,000 |
7,145,000,000 |
839,000,000 |
|
2008 |
11,274,000,000 |
6,063,000,000 |
355,000,000 |
The latest
financials are not available, and the Subject Company does not have any
obligations to release its financials to the public.
|
Authorized Capital(KRW) |
840,000,000 |
|
Paid-Up Capital(KRW) |
210,000,000 |
|
Total Issued Shares |
21,000 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
As of 12/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Total Assets |
9,887,197,000 |
9,780,604,000 |
9,350,890,000 |
|
Current Assets |
7,975,946,000 |
7,863,457,000 |
7,400,036,000 |
|
-Quick Assets |
- |
- |
- |
|
-Inventories |
- |
- |
- |
|
Fixed Assets |
1,911,251,000 |
1,917,147,000 |
1,950,854,000 |
|
-Investment |
- |
- |
- |
|
-Tangibles |
- |
- |
- |
|
-Intangibles |
- |
- |
- |
|
Total Liabilities |
5,493,954,000 |
5,577,812,000 |
5,335,017,000 |
|
Current Liabilities |
424,416,000 |
1,526,170,000 |
1,654,387,000 |
|
Fixed Liabilities |
5,069,538,000 |
4,051,642,000 |
3,680,630,000 |
|
Capital Stock |
210,000,000 |
210,000,000 |
210,000,000 |
|
Capital Surplus |
- |
- |
- |
|
Profit Surplus |
4,183,243,000 |
3,992,792,000 |
3,805,873,000 |
|
Capital Adjustment |
- |
- |
- |
|
Total Equity |
4,393,243,000 |
4,202,792,000 |
4,015,873,000 |
|
Liab. & Shareholder’s Equity |
9,887,197,000 |
9,780,604,000 |
9,350,890,000 |
|
Income Statement |
|||
|
Unit : Korean Won |
As of 12/31/2013 |
As of 12/31/2012 |
As of 12/31/2011 |
|
Sales |
12,803,737,000 |
14,918,541,000 |
13,958,606,000 |
|
Cost of Sold Goods |
10,995,237,000 |
12,548,232,000 |
11,619,643,000 |
|
Gross Profit |
1,808,500,000 |
2,370,309,000 |
2,338,963,000 |
|
Selling & Admin. Expenses |
1,389,452,000 |
1,850,831,000 |
1,455,759,000 |
|
Operating Income |
419,048,000 |
519,478,000 |
883,204,000 |
|
Non-Operating Income |
152,100,000 |
102,393,000 |
90,693,000 |
|
Non-Operating Expenses |
269,874,000 |
283,337,000 |
374,852,000 |
|
Income Before Taxes |
301,274,000 |
338,534,000 |
599,045,000 |
|
Income Taxes Expenses |
110,823,000 |
151,615,000 |
120,580,000 |
|
Net Income |
190,451,000 |
186,919,000 |
478,465,000 |
|
Main Products & Services |
Pharmaceuticals, Cosmetics, Chemicals |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Suppliers |
|
|
Customers |
|
|
Competitors |
GEO-YOUNG CORPORATION 421-1, YEONHUI-DONG, SEODAEMUN-GU, SEOUL,
KOREA TEL:+82-2-3662-8222 FAX:+82-2-3141-6492 BONA MEDICAL SUPPLY CO., LTD. 787, JUNG-RI, DONGTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-377-8091 FAX:+82-31-377-8095 BOKSAN PHARM. CO., LTD. 825-13, BEOMIL 2-DONG, DONG-GU, BUSAN,
KOREA TEL:+82-51-667-1511 FAX:+82-51-645-2365 |
The Subject imports
from New Zealand and China.
Not Available.
----------
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.92 |
|
|
1 |
Rs.93.57 |
|
Euro |
1 |
Rs.67.34 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.